The results of a british study showing that the drug dexamethasone reduces mortality in patients with severe Covid-19 are “quite promising,” commented Tuesday, Steven Van Gucht, the head of the department of viral diseases Sciensano. The institute of health is currently considering whether it is necessary to revise its recommendations for the hospitals.
The leaders of the clinical trial british Recovery, led by the university of Oxford, have discovered that dexamethasone, the drug of the family of steroids, reduce by one third the mortality in patients with the most severely affected. Some 2,000 hospitalized patients have received this substance.
